Exothera and Quantoom Biosciences Partner on mRNA Production
The research on future mRNA-based therapeutics, as well as their development and manufacturing, depends on fast and ecnomical production of RNAs.
Stay updated with breaking news from Quantoom Nfinity. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The research on future mRNA-based therapeutics, as well as their development and manufacturing, depends on fast and ecnomical production of RNAs.
Exothera has partnered with Quantoom Biosciences to gain access to Quantoom’s Nfinity technology, a continuous production platform for RNA. The partnership will enable Exothera to be the first CDMO in the world to offer this off-the-shelf process for the continuous production of RNA as a service. Continuous manufacturing of RNA can provide significant advantages in terms of efficiency, productivity, quality control, cost-effectiveness, and scalability.